Primary Pulmonary Hypertension News - Menu Thomson PPS Launches New Hypertension Web Site SECAUCUS, N.J., Aug. 30, 2005 - Nearly one in three American adults suffers from high blood pressure (hypertension), according to the American Heart Association. In an effort to help clinicians prevent or minimize their patients' serious health conditions that result from high blood pressure, the National Campaign to Control Hypertension(sm) (NCCH(sm)) is launching its Web site, controlhypertension.org. (http://www.controlhypertension.org) The NCCH is a medical education initiative offering a wide range of programs and activities to enhance clinicians' knowledge of hypertension and to identify clinically effective ways to reduce its associated risks. This initiative is sponsored by Thomson Professional Postgraduate Services (PPS), a part of The Thomson Corporation (NYSE: TOC; TSX: TOC) - a leader in information solutions for healthcare and scientific professionals. The NCCH is funded by an unrestricted educational grant from Novartis Pharmaceuticals Corporation. "Controlhypertension.org gives physicians and other healthcare professionals a single source for current, clinically relevant, and useful hypertension information," says NCCH co-chairperson Suzanne Oparil, MD. "What makes it different from other Web sites is not only its comprehensiveness, but also its timeliness." Uncontrolled high blood pressure is a risk factor in many cardiovascular outcomes including diabetes, heart failure, myocardial infarction, and kidney disease. Controlhypertension.org is designed specifically for the needs of primary-care physicians, specialists, and other healthcare professionals who treat patients with hypertension. Controlhypertension.org provides physicians and healthcare professionals with practical tools including: * a comprehensive slide library (updated monthly) * literature reviews (updated monthly) * cardiovascular news (updated daily) * a continuing medical education (CME)-certified newsletter * a clinical trials resource center Plus, the Web site offers patient education materials and an events calendar where registered users can enroll for NCCH programs. The literature reviews include expert commentary from NCCH faculty who give the clinical data context to help healthcare professionals manage their challenging clinical issues. Other areas of the site are updated when major breakthroughs occur so that users have immediate access to the latest information. As controlhypertension.org expands, it will contain more CME activities including interactive case studies. Thomson PPS Web sites such as lipidhealth.org and ndei.org consistently receive health industry awards for their comprehensive content and user-friendly navigation. Both of these sites have won awards from e-Healthcare Leadership. Last year, lipidhealth.org was awarded Best Healthcare Web Site of the Year by Medical Marketing & Media (MM&M). THE THOMSON CORPORATION
PPS Contact: Jennifer True SVP, Account Management U.S. (201) 271-6250 mailto:jennifer.true@pps.thomson.com Media Contact: Bradley James Hein Strategic Marketing U.S. (303) 486-6503 mailto:bradley.james@thomson.com Scientific Publication on Long-term Bosentan Use in PPH CHICAGO--(BUSINESS WIRE)--Jan 31, 2005 - Fitch Ratings has affirmed Wyeth's 'A-' senior unsecured credit rating and 'F2' commercial paper rating.
Wyeth Reports Results for the 2004 Fourth Quarter and Full Year MADISON, N.J., January 31, 2005 /PRNewswire-FirstCall/ -- Wyeth today reported results for the 2004 fourth quarter and full year. Worldwide net revenue increased 7% to $4.6 billion for the 2004 fourth quarter and 10% to $17.4 billion for the 2004 full year.
Victims, Attorneys Praise New Ruling in Fen-Phen Litigation; Ruling Allows Key Evidence in Thousands of Heart Valve Cases, Says Majority Counsel
DALLAS, May 26, 2004 /PRNewswire/ -- The following was released today by Majority Counsel:
Ambrisentan Phase II Results Presented at ATS 2004
DENVER, May 24, 2004 /PRNewswire-FirstCall/ -- Myogen, Inc. (NASDAQ:MYOG) , a biopharmaceutical company focused on the discovery, development and commercialization of small molecule therapeutics for the treatment of cardiovascular disorders, announced that Lewis Rubin, M.D. presented detailed results of AMB-220, the Company's Phase II safety and efficacy study of ambrisentan in patients with pulmonary arterial hypertension (PAH), at a mini symposium on "Emerging Therapies for PAH" at the American Thoracic Society (ATS) 2004 International Conference.
Record Fen-Phen Judgment Upheld; Judge and Jury Outraged By Evidence Proving Wyeth Knowingly Sold Harmful Drug, Says Majority Counsel
BEAUMONT, Texas, May 17, 2004 /PRNewswire/ -- The following was released today by Majority Counsel:
Freedland, Farmer, Russo & Sheller PL Prepares Phen-fen Case Similar To Recent $1 Billion Verdict; Family Sues Drug-maker, Hospital and Doctor for Mother's Death
WESTON, Fla.--(BUSINESS WIRE)--Apr 30, 2004 - Coming on the heels of a Texas jury's $1 billion award to the family of a woman who died after taking one of the now banned phen-fen diet drugs, Freedland, Farmer, Russo & Sheller PL await a trial date for a strikingly similar case against Wyeth-Ayerst Laboratories.
Wyeth to Appeal Verdict in Diet Drug Case
MADISON, N.J., April 27, 2004 /PRNewswire-FirstCall/ -- Wyeth (NYSE:WYE) said today it will appeal today's verdict in the case of Jerry Coffey (representing the estate of Cynthia Cappel-Coffey), et al. v. Wyeth, et al.
Landmark Judgment in Fen-Phen Trial
BEAUMONT, Texas, April 27 /PRNewswire/ -- The following was released today by Majority Counsel:
A Beaumont, Texas jury today returned a more than $1 billion verdict against Wyeth-Ayerst Laboratories in a landmark Fen-Phen trial. Experts predict that this outcome against drug-maker Wyeth will set the standard by which the company will be judged in the tens of thousands of Fen-Phen cases currently in the court system awaiting trial dates.
Phen-Fen's Hazards Emerge Anew; Family Sues Drug-Maker, Hospital & Doctor for Mother's Death According to Freedland, Glassman, Farmer & Sheller
WESTON, Fla.--(BUSINESS WIRE)--March 22, 2004--After almost a decade of stories of death and illness, billions of dollars in settlements, and persistent fears about Phen-Fen's damaging effects on those who've used it, news is emerging about lingering health risks related to the once-popular diet drug.
Actelion announces Full Year 2003 financial results
ALLSCHWIL/BASEL, SWITZERLAND - March 2, 2004 - Actelion Ltd (SWX: ATLN) today announced its financial results for the year 2003. With net revenues of CHF 307.5 million (FY 2002: CHF 132.4 m) and operating expenses of CHF 309.2 million (FY 2002: 164.5 m), the company reported an operating loss of CHF 1.7 million (FY 2002 loss: 32.0 m), mainly the result of a one-time In-Process R&D charge, related to the acquisition of Axovan in late 2003.
Profile Signs Inhaler Agreement with Schering
WEST SUSSEX, England, Oct. 24, 2003--Profile Therapeutics plc ("Profile"), which develops and commercialises specialist inhaled therapies, is delighted to announce the signing of an agreement with Schering Health Care Ltd. ("Schering"), a division of Schering AG.
HIV Patients with Pulmonary Arterial Hypertension (PAH): Results of Treatment with Oral Tracleer (bosentan)
ALLSCHWIL/BASEL, Switzerland, Sept. 2, 2003 - Actelion Ltd (SWX: ATLN) today announced results of a study assessing its oral dual endothelin receptor antagonist (ERA) Tracleer® (bosentan) in the treatment of pulmonary arterial hypertension (PAH) related to HIV (human immunodeficiency virus) infection.
New analysis suggests treatment with Tracleer (bosentan) is associated with improved survival in primary pulmonary hypertension patients
ALLSCHWIL/BASEL, SWITZERLAND - May 19, 2003 - Actelion Ltd (SWX: ATLN) today announced the analysis of long-term follow-up data of primary pulmonary hypertension patients from Tracleer® pivotal registration studies.
Aradigm and geneRx+ Announce Drug Delivery Collaboration for Gene-Based Therapeutics
HAYWARD, Calif. and ATLANTA, Sept. 26, 2002 /PRNewswire-FirstCall/ -- Aradigm Corporation (NASDAQ: ARDM) , a leader in pulmonary drug delivery and geneRx+, an innovator in protein and gene-based technologies, today
Deadline Set for Those Who Opted Out of the Fen-Phen Settlement, Says Attorney Michael Hackard
SACRAMENTO, Calif., Jan. 10, 2002 -- People who have opted out of the class-action lawsuit against American Home Products and
Deaths, Lawsuits on Rise as Fen-Phen Withdrawal Approaches 4-Year Anniversary; Cases Against Diet Drug Manufacturer Could Double, Says Leading Pharmaceutical Attorney Michael Hackard
SACRAMENTO, Sept. 10, 2001 -- Two wrongful death complaints filed today in California could signal a renewed wave of lawsuits against American Home Products just as the pharmaceutical company coaxes investors back with predictions that its legal troubles over Fen-Phen/Redux are coming to an end.
The Faces of Fen-Phen; All They Wanted Was to Lose Weight; Now Their Families Face a Bigger Loss
SACRAMENTO, Calif., Sept. 10, 2001 -- Donald Holmes of San Juan Bautista was the 63-year-old owner of a trucking company
AMERICAN HOME PRODUCTS CORPORATION REPORTS STRONG OPERATING RESULTS
MADISON, N.J., Jan. 25, 2001 -- American Home Products Corporation (the Company) (NYSE: AHP) today reported net revenue and results of operations for the 2000 fourth quarter and full year.
National Diet Drug Class Action Against French Pharmaceutical Giant Cleared to Proceed
Access to Justice for 155,000 Canadians
TORONTO, Nov. 22, 2000 - Access to justice for more than 155,000 Canadians who took the diet pills Ponderal and Redux which are alleged to cause serious illnesses is now a reality following an important ruling released today from Madam Justice Susan Gray of the Ontario Divisional Court.
American Home Products Corporation Reports Continued Strong Sales and Earnings From Continuing Operations for the 2000 Third Quarter and First Nine Months
MADISON, N.J., Oct. 19, 2000 -- American Home Products Corporation (the Company) (NYSE: AHP) today reported sales and earnings results for the 2000 third quarter and first nine months.
United Therapeutics Corporation: Pulmonary Hypertension Clinical Trial Discussed at Seminar Associated With European Cardiology Conference
SILVER SPRING, Md. and RESEARCH TRIANGLE PARK, N.C., Aug. 28, 2000 -- United Therapeutics Corporation (Nasdaq: UTHR) announced today that results of its Phase III clinical trial of Uniprost (also known as UT-15) for pulmonary hypertension -- the largest double blinded placebo-controlled pulmonary hypertension study -- were presented today at a satellite symposium organized for clinicians attending the European Society of Cardiology's annual meeting in Amsterdam, The Netherlands.
Glaxo Wellcome's Flolan Now Approved for a New Use
Research Triangle Park, NC, (May 2, 2000)-Glaxo Wellcome Inc. announced today that Flolan‚ brand epoprostenol sodium for Injection, a treatment for severe cases of primary pulmonary hypertension (New York Heart Association (NYHA) classes III & IV), has now received approval for a new indication, the long-term intravenous treatment of pulmonary hypertension secondary to scleroderma spectrum of diseases (PH/SSD, NYHA classes III & IV) for patients who do not respond to conventional therapy.
American Home Products CEO Forced to Testify in Fen-Phen Case
HOUSTON, March 13, 2000 -- Fleming & Associates, L.L.P., lead counsel for two severely injured Sioux Falls, South Dakota, women who ingested Fen-Phen, has successfully petitioned the court to order John R. Stafford, chairman, president and CEO of American Home Products Corporation (NYSE: AHP) (AHP), to undergo an immediate deposition by plaintiffs’ attorney George M. Fleming.
|